Jan. 16 at 9:12 PM
$IOVA That
$150+ figure in the IOVA atalist picture did not come from any analyst report or public forecast. It’s a purely illustrative bull-case number that is used to visualise wat could be the stockprice if all major catalysts succeed and the platform proves broadly valuable. So in the image:
$10 = illustrative base case anchor (roughly “today + modest execution”) /
$25–
$50+ = milestone-driven reratings (approval, expansion, pipeline progress) /
$150+ = a theoretical long-term bull case where:
- Lifileucel becomes a category-defining therapy
- Multiple solid tumor indications succeed
- Iovance evolves into a platform oncology company
It is not a consensus target, not a street estimate, and not something you’ll find on Yahoo, TipRanks, or in any bank note. It represents: “What the market could pay in a best-case multi-year outcome if everything works.”
